FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Carcinogenesis
/ drug effects
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Docetaxel
/ pharmacology
Gene Expression Regulation, Neoplastic
Humans
Male
Mice
Nucleotidyltransferases
/ metabolism
PTEN Phosphohydrolase
/ metabolism
Polynucleotide Adenylyltransferase
/ metabolism
Prostatic Neoplasms
/ drug therapy
Proto-Oncogene Proteins c-akt
/ metabolism
Signal Transduction
/ drug effects
Xenograft Model Antitumor Assays
FAM46C
PTEN
prostate cancer
tumorigenesis
ubiquitination
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
13 04 2020
13 04 2020
Historique:
received:
27
09
2019
accepted:
23
02
2020
pubmed:
14
4
2020
medline:
26
2
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
Family with sequence similarity 46 member C (FAM46C) is a non-canonical poly(A) polymerase that is associated with tumorigenesis. However, its role in prostate cancer development is not fully understood. Herein, we determined expression pattern of FAM46C in prostate cancer and further identified its effect on the tumorigenesis and chemosensitivity. FAM46C expression was decreased in prostate cancer tissues and cell lines compared with corresponding controls. FAM46C expression was significantly associated with the Gleason score, tumor size and overall survival. FAM46C knockdown in 22RV1 and DU145 cells significantly inhibited apoptosis and promoted cell proliferation and cell cycle progression as well as activation of AKT. FAM46C overexpression had an inverse effect in DU145 cells and inhibited tumor growth
Identifiants
pubmed: 32283544
doi: 10.18632/aging.103030
pii: 103030
pmc: PMC7185131
doi:
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Nucleotidyltransferases
EC 2.7.7.-
TENT5C protein, human
EC 2.7.7.-
Fam46c protein, mouse
EC 2.7.7.19
Polynucleotide Adenylyltransferase
EC 2.7.7.19
PTEN Phosphohydrolase
EC 3.1.3.67
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6352-6369Références
Clin Cancer Res. 2014 Sep 1;20(17):4689-704
pubmed: 24987055
Artif Cells Nanomed Biotechnol. 2018 Nov;46(7):1495-1504
pubmed: 28889753
Arthritis Res Ther. 2010;12 Suppl 1:S5
pubmed: 21303493
Iran J Allergy Asthma Immunol. 2018 Aug 12;17(4):318-325
pubmed: 30537795
Front Oncol. 2013 Apr 12;3:85
pubmed: 23596569
Mod Pathol. 2013 Mar;26(3):435-47
pubmed: 23018874
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):115-120
pubmed: 29496690
Cancer Res. 2017 Aug 15;77(16):4317-4327
pubmed: 28619709
Int J Oncol. 2018 Mar;52(3):945-954
pubmed: 29393396
Prostate. 2005 Jan 1;62(1):61-8
pubmed: 15389810
Clin Cancer Res. 2007 Jul 1;13(13):3860-7
pubmed: 17606718
Cell Death Dis. 2018 Jan 23;9(2):78
pubmed: 29362431
Cancer Res. 2007 Jul 15;67(14):6535-8
pubmed: 17638861
Sci Rep. 2017 Mar 24;7(1):396
pubmed: 28341836
Nat Neurosci. 2016 Mar;19(3):443-53
pubmed: 26780512
Sci Rep. 2018 May 18;8(1):7820
pubmed: 29777112
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Urology. 2014 Jan;83(1):146-52
pubmed: 24238563
BMC Cancer. 2018 Jan 2;18(1):8
pubmed: 29295717
Exp Mol Med. 2018 Dec 10;50(12):1-12
pubmed: 30532005
Prostate. 2010 Feb 1;70(2):135-46
pubmed: 19784964
JAAPA. 2014 Aug;27(8):14-20; quiz 26
pubmed: 24988136
Oncogene. 2010 May 6;29(18):2712-23
pubmed: 20190811
Genomics. 2009 Sep;94(3):153-60
pubmed: 19540335
Nat Commun. 2017 Sep 20;8(1):619
pubmed: 28931820
Biol Res Nurs. 2018 Mar;20(2):218-226
pubmed: 29325451
Ann Surg Oncol. 2017 Oct;24(11):3438-3445
pubmed: 27770343
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):272-84
pubmed: 14734480
Oncogene. 2002 Sep 26;21(43):6587-97
pubmed: 12242656
Am J Transl Res. 2017 Jan 15;9(1):155-166
pubmed: 28123642
Neoplasma. 2015;62(1):34-40
pubmed: 25563365
Toxicol Appl Pharmacol. 2016 Nov 15;311:113-116
pubmed: 27720938
Clin Cancer Res. 2011 Dec 15;17(24):7776-84
pubmed: 21994415
Cancer Res. 2006 Jul 15;66(14):6998-7006
pubmed: 16849544
Neurosci Lett. 2016 Mar 23;617:232-5
pubmed: 26917099
J Drug Target. 2014 Feb;22(2):146-55
pubmed: 24147456
Oncotarget. 2017 Sep 8;9(1):428-441
pubmed: 29416625
Mod Pathol. 2010 May;23(5):703-12
pubmed: 20208477
EMBO J. 2017 May 15;36(10):1434-1446
pubmed: 28363942
Neuro Oncol. 2014 Nov;16(11):1499-509
pubmed: 24968695
Semin Oncol. 2002 Jun;29(3 Suppl 11):62-70
pubmed: 12138399